|
|
Characterization and the Anti-tumor Effect of Doxorubicin Flexible Liposome in vitro |
GUO Chun-fang, ZHANG Yang-de, WANG Ji-wei, PAN Yi-feng, LIAO Ming-mei, WANG Ning |
Ministry of Health Hepatobiliary & Enteric Surgery Research Center, Central South University, Changsha 410008, China |
|
|
Abstract Objective: To evaluate the potential application of flexible nanoliposomes containing membrane softening agent in intravenous administration by comparing doxorubicin (DOX) load capability and tumor cell inhibition of different nanoliposomes. Methods: Traditional liposomes (DOX-CL) and flexible nanoliposomes (DOX-FNL) were prepared by film hydration method with DOX as a model drug. Encapsulation efficiency of liposomes were investigated by Dextran gel chromatography column method. The hydrodynamic size, zeta potential and polydispersity index (PDI) of liposomes in different pH condition and media were characterised by particle size analyzer. The drug release of two liposomes in vitro were detected with membrane dialysis method. The human breast cancer MCF-7cell viability of two liposomes were investigated with MTT assay. The cell cycle changes of MCF-7 cells induced by DOX-CL and DOX-FNL were detected by flow cytometry. Results The encapsulation efficiency of DOX-FNL was higher than DOX-CL, and the DOX-FNL had more excellent suspension stability in neutral pH conditions, water, physiological saline, PBS and RPMI-1640 culture medium with/without 10% FBS. The release rate of two liposomes was no significant difference (P>0.05) in different pH conditions. The cytotoxic detection results showed that the inhibition of MCF-7 cells was hardly different between DOX-CL and DOX-FNL, while tumor cell killing effect of DOX-FNL was more endurable than DOX-CL(P<0.05). The FCM detection results showed that the cell cycle of MCF-7 arrested in G0/G1 phase by DOX-FNL was similar as the DOX-CL, moreover, DOX-FNL is more effective than DOX-CL(P<0.05). Conclusion DOX-FNL has higher drug encapsulation efficiency and stability than DOX-CL. DOX-FNL can affect the cell cycle, and its drug action time is significantly higher than DOX-CL.
|
Received: 24 January 2013
Published: 25 March 2013
|
|
|
|
[1] Mustafa M E, Ossama Y A, Viviane F N, et al. Lipid vesicles for skin delivery of drugs: reviewing three decades of research. International Journal of Pharmaceutics, 2007, 332: 1-16. [2] Gillet A, Lecomte F, Hubert P, et al. Skin penetration behaviour of liposomes as a function of their composition. European Journal of Pharmaceutics and Biopharmaceutics, 2011, 79: 43-53. [3] Honeywell N, Arenja, Bouwstra. Skin penetration and mechanisms of action in the delivery of the D2-agonist rotigotine from surfactant-based elastic vesicle formulations. Pharm. Res, 2003, 20: 1619-1625. [4] Honeywell N, Bouwstra. The in vitro transport of pergolide from surfactant-based elastic vesicles through human skin: a suggested mechanism of action. J. Control. Release, 2003, 86: 145-156. [5] Zheng W S, Fang X Q, Wang L L, et al. Preparation and quality assessment of itraconazole transfersomes. International Journal of Pharmaceutics, 2012, 436: 291-298. [6] Pathomthat S, Phensri T, Uracha R, et al. Physico-chemical characteristics of methotrexate-entrapped oleic acid-containing deformable liposomes for in vitro transepidermal delivery targeting psoriasis treatment. International Journal of Pharmaceutics, 2012, 427: 426-434. [7] Huang Y B, Tsai M J, Wu P C, et al. Elastic liposomes as carriers for oral delivery and the brain distribution of (+)-catechin. Journal of Drug Targeting, 2011, 19(8): 709-718. [8] Li W Z, Zhou Y Q, Zhao N, et al. Pharmacokinetic behavior and efficiency of acetylcholinesterase inhibition in rat brain after intranasal administration of galanthamine hydrobromide loaded flexible liposomes. Environmental Toxicology and Pharmacology, 2012, 34: 272-279. [9] Torchilin V P, Weissig V.脂质体.第二版,北京:化学工业出版社,2005:208. Torchilin V P, Weissig V. Liposomes. 2ed. Beijing: Chemical Industry Press, 2005:208. [10] Kaur I P, Bhandari R, Bhandari S, et al. Potential of solid lipid nanoparticles in brain targeting. J Control Release, 2008, 127: 97-109. [11] Xie Y, Ye L, Zhang X, et al. Transport of nerve growth factor encapsulated into liposomes across the blood brain barrier: in vitro and in vivo studies. J Control Release, 2005, 105: 106-119. |
|
Viewed |
|
|
|
Full text
|
|
|
|
|
Abstract
|
|
|
|
|
Cited |
|
|
|
|
|
Shared |
|
|
|
|
|
Discussed |
|
|
|
|